Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Therapie ; 76(3): 215-219, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32951867

RESUMO

Patients with auto-immune disease are more susceptible to infection than similar populations without auto-immune disease. Vaccination seems to be one of the most effective methods to prevent patients from possible infections, but may be impaired by concomitant immunomodulators. The aim of this review was to evaluate the effect of immunosuppressive drugs on vaccination efficiency. We found that the majority of studies confirms that neither the use of corticosteroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) nor the use of biological agents, except rituximab, reduce the efficacy of inactivated vaccines such as pneumococcal and influenza vaccines. Even if rituximab has been shown to reduce humoral responses following influenza and pneumococcal vaccination, this response can be modestly restored 6-10 months after rituximab administration. To sum up, treatment guidelines recommending routine use of pneumococcal and influenza vaccines for immune compromised patients should be followed in order to avoid severe infections.


Assuntos
Antirreumáticos , Vacinas contra Influenza , Doenças Reumáticas , Antirreumáticos/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Vacinas contra Influenza/uso terapêutico , Doenças Reumáticas/tratamento farmacológico , Vacinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...